Companies · Pharmaceuticals

Zelos Therapeutics Inc

WEST CONSHOHOCKEN · Pharmaceuticals

Diligence memoA one-page analyst read on Zelos Therapeutics Inc — recommendation, valuation, rhythm, risks.
$17.8M
Total raised · real
6
Rounds
0.9×
Latest step-up
Top 37%
Sector rank · raised
Series A
Latest stage · inferred · Wed Mar 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Zelos Therapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.42× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Zelos Therapeutics Inc is one of 1613 Pharmaceuticals companies tracked from WEST CONSHOHOCKEN. By capital raised it ranks mid-pack (ahead of 64% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2009-03-03 Raised $1.0M (real) Modeled valuation $47M (est)$1.0M$47MPre-Seed2009Seed · 2009-03-03 Raised $1.5M (real) Modeled valuation $57M (est)$1.5M$57MSeed2009Series A · 2009-05-29 Raised $9.1M (real) Modeled valuation $283M (est)$9.1M$283MSeries A2009Series A · 2010-05-07 Raised $922K (real) Modeled valuation $29M (est)$922K$29MSeries A2010Series A · 2011-08-03 Raised $2.8M (real) Modeled valuation $87M (est)$2.8M$87MSeries A2011Series A · 2012-03-07 Raised $2.4M (real) Modeled valuation $75M (est)$2.4M$75MSeries A2012+$1.5M+$9.1M+$922K+$2.8M+$2.4MCumulative $18M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2009
Seed$1.5M · 2009
Series A$9.1M · 2009
Series A extension$922K · 2010
Series A extension$2.8M · 2011
Series A extension$2.4M · 2012

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$75.0M
Base estimate est.
$2.8M
Conservative case
$407.9M
Upside case
$11.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $47.3M · 2009-03-032009Seed · modeled $57.1M · 2009-03-03Series A · modeled $282.6M · 2009-05-29Series A · modeled $28.6M · 2010-05-07Series A · modeled $86.5M · 2011-08-03Series A · modeled $75.0M · 2012-03-072012
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
14.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$5.9M/yr
Capital velocity
17.3 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.2× above median
This company$17.8M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.5× of median
This company$2.4M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 1.0× of median
This company$75.0M
Sector median$76.1M

Raised more than 64% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #47 of 57.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Satori Pharmaceuticals Inc · Series A Raised $22.3M · modeled $464.6M (est)Labrys Biologics, Inc. · Series A Raised $14.6M · modeled $451.8M (est)Telsar Pharma, Inc. · Series A Raised $14.0M · modeled $433.7M (est)Acetylon Pharmaceuticals, Inc. · Series A Raised $33.6M · modeled $433.2M (est)Seldar Pharma, Inc. · Series A Raised $18.2M · modeled $402.6M (est)Link Resources Inc. · Series A Raised $12.0M · modeled $371.7M (est)Scynexis Inc · Series A Raised $22.7M · modeled $354.6M (est)Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) · Series A Raised $30.5M · modeled $334.7M (est)BioNumerik Pharmaceuticals, Inc. · Series A Raised $11.3M · modeled $315.6M (est)Tioga Pharmaceuticals Inc · Series A Raised $24.3M · modeled $309.7M (est)Bonovo Orthopedics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Quark Pharmaceuticals Inc · Series A Raised $10.0M · modeled $309.7M (est)Zelos Therapeutics Inc (this company) Raised $17.8M · modeled $75.0M (est)Zelos Therapeutics Inc
CompanyStageRaised · realValue · estvs peer med.
Satori Pharmaceuticals IncSeries A$22.3M$464.6M2.58×
Labrys Biologics, Inc.Series A$14.6M$451.8M2.51×
Telsar Pharma, Inc.Series A$14.0M$433.7M2.41×
Acetylon Pharmaceuticals, Inc.Series A$33.6M$433.2M2.40×
Seldar Pharma, Inc.Series A$18.2M$402.6M2.23×
Link Resources Inc.Series A$12.0M$371.7M2.06×
Scynexis IncSeries A$22.7M$354.6M1.97×
Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)Series A$30.5M$334.7M1.86×
BioNumerik Pharmaceuticals, Inc.Series A$11.3M$315.6M1.75×
Tioga Pharmaceuticals IncSeries A$24.3M$309.7M1.72×
Bonovo Orthopedics, Inc.Series A$10.0M$309.7M1.72×
Quark Pharmaceuticals IncSeries A$10.0M$309.7M1.72×
Zelos Therapeutics Inc this companySeries A$17.8M$75.0M0.42×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2009-03-03$5.6M$47.3M90%
Seed$1.5M2009-03-03$7.5M$57.1M90%
Series A$9.1M2009-05-29$41.5M$282.6M90%
Series A$922K2010-05-07$4.2M$28.6M90%
Series A$2.8M2011-08-03$12.7M$86.5M90%
Series A$2.4M2012-03-07$11.0M$75.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2009-03-03
    • First recorded raise — entered as Pre-Seed.
  2. Seed$1.5M2009-03-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
  3. Series A$9.1M2009-05-29
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 6.1× larger than the prior — scaling up.
  4. Series A$922K2010-05-07
    • Raised 11 mo later, in step with the ~13 mo sector norm.
    • Round 9.9× smaller than the prior — bridge or down round.
  5. Series A$2.8M2011-08-03
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round 3.0× larger than the prior — scaling up.
  6. Series A$2.4M2012-03-07
    • Came back fast: 7 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2012 ~Q4
Modeled next raise · ~7mo cadence
$2.4M
Modeled next size est.range $2.4M$3.9M
0.9×
Last step-up
$5.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Joseph Zakrzewski5 other2009-03
Colin Goddard4 other2009-03
Farah Champsi4 other2009-03
Brian MacDonald3 other2009-03
Alex Barkas2 other2009-03
David Krause2 other2009-03
Donald Hayden2 other2012-03
Jaisim Shah2 other2010-05
Jeff Courtney2 other2009-03
Alan Roemer1 other2009-03
Cynthia Lavoie1 other2011-08
Jeffrey Courtney1 other2010-05
Joan Lau2012-03
Lily Lam2012-03
Registry & provenance

Zelos Therapeutics Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1286667
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
SiteOne Therapeutics, Inc.PharmaceuticalsSeries A$16.1M$460.3Mnetwork1 shared operator · same sector · same stage
Vitae Pharmaceuticals, IncPharmaceuticalsSeries A$15.0M$464.6Mnetwork1 shared operator · same sector · same stage
Merganser Biotech, Inc.BiotechnologySeries A$21.1M$473.5Mnetwork2 shared operators · same stage
Zikani Therapeutics, Inc.PharmaceuticalsSeries A$31.7M$232.3Mnetwork1 shared operator · same sector · same stage
Cornerstone Pharmaceuticals IncPharmaceuticalsSeries A$17.8M$102.5Msame sector · same stage
Moleculin, LLCPharmaceuticalsSeries A$17.6M$42.8Msame sector · same stage
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$17.5M$31.4Msame sector · same stage
Spectrum Antimicrobials, Inc.PharmaceuticalsSeries A$17.3M$47.3Msame sector · same stage
Frequently asked
How much funding has Zelos Therapeutics Inc raised?
Zelos Therapeutics Inc has raised approximately $17.8M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Zelos Therapeutics Inc's estimated valuation?
Provath's modeled valuation for Zelos Therapeutics Inc is approximately $75.0M (modeled range $2.8M–$407.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Zelos Therapeutics Inc at?
Zelos Therapeutics Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Mar 07.
What does Zelos Therapeutics Inc do and where is it based?
Zelos Therapeutics Inc operates in the Pharmaceuticals sector, based in WEST CONSHOHOCKEN.
Explore related

See where Zelos Therapeutics Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Zelos Therapeutics Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.